- Omapatrilat
-
Omapatrilat Systematic (IUPAC) name (4S,7S,10aS)-5-oxo-4-{[(2S)-3-phenyl-2- sulfanylpropanoyl]amino}-2,3,4,7,8,9,10,10a-octahydropyrido[6,1-b] [1,3]thiazepine-7-carboxylic acid Clinical data Pregnancy cat. ? Legal status ? Identifiers CAS number 167305-00-2 ATC code None PubChem CID 656629 UNII 36NLI90E7T ChEMBL CHEMBL289556 Chemical data Formula C19H24N2O4S2 Mol. mass 408.534 g/mol (what is this?) (verify) Omapatrilat (INN) is a novel antihypertensive agent that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling.
This drug from Bristol-Myers Squibb was not approved by the U.S. Food and Drug Administration due to angioedema safety concerns.[1]
References
- ^ Joshi Venugopal. (2003) Pharmacological modulation of the natriuretic peptide system. Expert Opinion on Therapeutic Patents 13:9, 1389
Categories:- ACE inhibitors
- Propionamides
- Lactams
- Thiols
- Carboxylic acids
- Antihypertensive agent stubs
Wikimedia Foundation. 2010.